Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Non Operating Income (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Non Operating Income for 6 consecutive years, with -$8.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 51.31% to -$8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.1 million, a 74.12% increase, with the full-year FY2025 number at -$8.1 million, up 72.6% from a year prior.
  • Non Operating Income was -$8.3 million for Q4 2025 at GeneDx Holdings, down from -$174000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $121.0 million in Q3 2021 to a low of -$17.1 million in Q4 2024.
  • A 5-year average of $10.2 million and a median of $123000.0 in 2024 define the central range for Non Operating Income.
  • Biggest YoY gain for Non Operating Income was 25350.0% in 2023; the steepest drop was 282400.0% in 2023.
  • GeneDx Holdings' Non Operating Income stood at $75.6 million in 2021, then tumbled by 100.0% to -$1000.0 in 2022, then crashed by 282400.0% to -$2.8 million in 2023, then crashed by 505.88% to -$17.1 million in 2024, then surged by 51.31% to -$8.3 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Non Operating Income are -$8.3 million (Q4 2025), -$174000.0 (Q3 2025), and $239000.0 (Q2 2025).